Investing in biotechnology equities offers the potential for high clinical and financial rewards, but it also carries significant binary risk tied to clinical trial readouts, regulatory approvals by agencies like the FDA, and capital-raising needs. Whether it is an opportune time depends entirely on an investor's risk appetite, asset diversification, and willingness to weather high volatility. What is your target allocation for high-risk biotechnology assets within your broader portfolio?